Zuha Jeddy

Zuha Jeddy

Auto-generated profile, based on publicly available information

Zuha Jeddy

Abt Associates Inc. , Rockville, Maryland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2024 in Journal of the Pediatric Infectious Diseases Society
Verified
Journal Article
Closed access
LFLeora R Feldstein
Leora R Feldstein
JRJasmine Ruffin
Jasmine Ruffin
RWRyan Wiegand
Ryan Wiegand
LGLauren Grant
Lauren Grant
TBTara M Babu
Tara M Babu
MGManjusha Gaglani
Manjusha Gaglani
To understand how coronavirus disease 2019 vaccines impact infection risk in children <5 years, we assessed risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from September 2022 to April 2023 in 3 cohort studies. There was no difference in risk by vaccination status. While vaccines reduce severe disease, they may not reduce SARS-CoV-2 infections in naïve young children.

1 August 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
ZLZoe Lyski
Zoe Lyski
CPCynthia Porter
Cynthia Porter
JUJennifer L Uhrlaub
Jennifer L Uhrlaub
KEKate Ellingson
Kate Ellingson
ZJZuha Jeddy
Zuha Jeddy
KLKaren Lutrick
Karen Lutrick
The PROTECT study is a longitudinal cohort study initiated in July 2021 with weekly testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 4 states: Arizona, Florida, exas, and Utah. This study aims to examine vaccine-elicited antibody response against postvaccination SARS-CoV-2 infections. Children aged 5–11 years had serum collected 14–59 days after their second dose of monovalent Pfizer-BioNTech coronavirus disease 2019 messenger RNA vaccine. Vaccine-elicited antibodies were measured using the area under the curve (AUC) and end-point titer using enzyme-linked immunosorbent assay (receptor-binding domain [RBD] and S2) and surrogate neutralization assays against ancestral (WA1) and Omicron (BA.2). 79 vaccinated participants (33 [41.7%] female; median age, 8.8 years [standard deviation, 1.9 years]), 48 (60.8%) were from Tucson, Arizona; 64 (81.0%) were non-Hispanic white; 63 (80.8%) attended school in person; 68 (86.1%) did not have any chronic conditions; and 47 (59.5%) were infected after vaccination. Uninfected children had higher AUCs against WA1 (P = .009) and Omicron (P = .02). The geometric mean and surrogate neutralization titer above the limit of detection was 346.0 for WA1 and 39.7 for Omicron, an 8.7-fold decrease (P < .001). After adjustment of covariates in the WA1-specific model, we observed a 47% reduction in the odds of postvaccination infection for every standard deviation increase in RBD AUC (aOR, 0.53 [95% confidence interval, .29–.97) and a 69% reduction in the odds of infection for every 3-fold increase in RBD end titer (0.31 [.06–1.57]). Children with higher antibody levels experienced a lower incidence of postvaccination SARS-CoV-2 infection.